ηγωεϊ εδεγςεϊ μςιϊεπεϊ
θας ψελωϊ ΰϊ IVAX ϊξεψϊ 7.4 ξιμιΰψγ γεμψ δψλιωδ ϊηζχ ΰϊ δξπδιβεϊ δβμεαμιϊ αϊηεν δϊψετεϊ δβπψιεϊ, ϊερισ χεει ξεφψιν ηγωιν εωεεχιν φεξηιν δηαψεϊ ιχιιξε ωιηϊ εςιγδ αωςδ 15:30 ωςεο ιωψΰμ, ΰωψ πιϊο ιδιδ μδΰζιο μδ γψκ ΰϊψι δΰιπθψπθ ωμδο.25/7/2005 θας ϊςωιεϊ τψξφαθιεϊ ας"ξ ε- IVAX Corporation δεγιςε διεν αξωεϊσ λι ηϊξε ςμ δρλν ξηιια μψλιωϊ IVAXςμ-ιγι θας. ςμ-τι ϊπΰι δδρλν λμ ξπιδ ψβιμδ ωμ IVAX ϊεξψ, ςμ-τι αηιψϊ ξηζιχ δξπιδ, μϊωμεν αξζεξο αρκ ωμ 26$ ΰε μ- 0.8471 ADR ωμ θας, αλτεσ μημεχδ ιηριϊ λκ ωμΰ ιεϊψ ξξηφιϊ ϊεξψ μξπιεϊ εμΰ ιεϊψ ξξηφιϊ ϊωεμν αξζεξο. δϊξεψδ δλεμμϊ ωμ δςιρχδ ϊδιδ λ- 7.4 ξιμιΰψγ $ αδϊαρρ ςμ ξηιψ δρβιψδ ωμ δ-ADR ωμ θας α- NASDAQ α- 5 διξιν ςγ ελεμμ δ- 22 αιεμι, 2005. φτει λι ςν δωμξϊ δςιρχδ ιηζιχε αςμι δξπιεϊ ωμ IVAX λ- % 15 αθας ςμ αριρ γιμεμ ξμΰ. δϊωμεν αξζεξο ιξεξο ξιϊψεϊ δξζεξπιν ωαψωεϊ θας εαχεει ΰωψΰι ωδεςξγε μθεαϊδ μφεψκ λκ. δγιψχθεψιεπιν ωμ ωϊι δηαψεϊ ΰιωψε τδ ΰηγ ΰϊ δςιρχδ.
ιωψΰμ ξχεα, πωιΰ εξπλ"μ θας, ΰξψ: "ζδε ιεν ξψβω εΰαο γψκ αδιρθεψιδ ωμ θας. IVAX, αγεξδ μθας, διπδ ημεφδ αΰρθψθβιεϊ δφξιηδ εδβμεαμιζφιδ. ΰιηεγ ωϊι δηαψεϊ ιςφιν ΰϊ ςξγϊ δξπδιβεϊ ωμπε αϊςωιιδ δβπψιϊ δβμεαμιϊ. ωιμεα ςρχιπε δξωμιξιν ζδ ΰϊ ζδ, ιΰτωψ μθας μδψηια εμηζχ ΰϊ δϊηεξιν δβπψι εδιιηεγι ςμ-ιγι δψηαϊ ρμ δξεφψιν ωμπε, φαψ ξεφψιν βγεμ ιεϊψ επεληεϊ πψηαϊ ιεϊψ αϊηεν δθιτεμι εαωεεχιν φεξηιν."
δωιμεα αιο IVAX εθας ιιηεγι αδϊΰξϊν ιεφΰϊ δγετο ωμ ωϊι δηαψεϊ. αδιαθ δβΰεβψτι μ- IVAX πεληεϊ ηζχδ αΰξψιχδ δμθιπιϊ εαξψλζ εαξζψη ΰιψετδ εατςιμεϊ ξωμιξδ μτςιμεϊδ ωμ θας αφτεο-ΰξψιχδ εαΰιψετδ. μ- IVAX βν χεει ξεφψιν ξωμιξιν αϊηεν δβπψι, τςιμεϊ ξωξςεϊιϊ αϊηεν ξεφψιν μθιτεμ ααςιεϊ πωιξδ, αϊηεν ξςψλϊ δςφαιν δξψλζιϊ, εαΰεπχεμεβιδ. ςμ αριρ δτςιμεϊ δπεληιϊ ωμ θας ε- IVAX εμΰηψ ρβιψϊ δςιρχδ ιδιε μθας ξλιψεϊ ωμ ξςμ μ- 7 ξμιΰψγ $, τςιμεϊ ιωιψδ αμξςμδ ξ- 50 ξγιπεϊ ελ- ,00025 ςεαγιν. δηαψδ δξΰεηγϊ ϊφις ρμ ξεφψιν, βπψιιν ειιηεγιιν, ψηα αιεϊψ μϊεςμϊ δφψλπιν, δμχεηεϊ ερτχι ωιψεϊι δαψιΰεϊ.
Dr. Phillip Frost, ιε"ψ εξπλ"μ IVAX ΰξψ: "ξζδ ζξο ψα μωϊι δηαψεϊ ιηρι ςαεγδ ειηριν ΰιωιιν θεαιν ξΰεγ. μ- IVAX δςψλδ ςξεχδ μρθπγψθιν δΰϊιιν δβαεδιν ςμ-τι δν τεςμϊ θας μΰεψκ λμ δωπιν μιφιψϊ ςψκ ξερσ μαςμι ξπιεϊιδ. ΰπε πψβωιν ξΰεγ ξδδζγξπεϊ μχηϊ ημχ αηιζεχ ξεαιμεϊδ ωμ θας λρτχιϊ ϊψετεϊ αςμεϊ ωεεδ μλμ πτω ελξτϊηϊ ϊψετεϊ ιιηεγιεϊ μψεεηϊ δφιαεψ."
ξψ ξχεα δερισ: "ψλιωϊ IVAX ϊεξλϊ ξωξςεϊιϊ αΰρθψθβιιδ ΰψελϊ δθεεη ωμπε φξιηδ ψεεηιϊ εξπδιβεϊ βμεαμιϊ. ΰπε ξΰξιπιν ωμωϊι δηαψεϊ ϊψαεϊ εςψλιν γεξιν , ΰωψ μμΰ ρτχ ιδεε ϊωϊιϊ ξεφμηϊ ωϊχμ ξΰεγ ςμ ϊχετϊ δξςαψ ειϊψξε μιφιψϊ ριπψβιεϊ ξωξςεϊιεϊ. ΰπε φετιν ωξιζεβ ζδ ιϊψεν μψεεη μξπιδ ωμπε αξδμκ δωπδ δψΰωεπδ."
μριλεν ΰξψ ξψ ξχεα: " θας ε- IVAX πχθε διεν αφςγ πεςζ ςμ ξπϊ μιφεψ ηαψδ ωΰπε ξΰξιπιν λι ϊδιδ δβγεμδ αιεϊψ αϊςωιιδ δβπψιϊ εϊιφεψ ςψκ ΰξιϊι μαςμι δξπιεϊ, μςεαγιδ εμμχεηεϊιδ."
ϊπΰι δςιρχδ
δςιρχδ, δξαερρϊ ςμ ξαπδ ξιζεβ ξωεμω εΰωψ ϊδτεκ ΰϊ IVAX - μηαψϊ αϊ ωμ θας, λτετδ μΰιωεψν ωμ αςμι δξπιεϊ ωμ θας εωμ IVAX εμχαμϊ διϊψιν ςμ-τι ηεχ δδβαμιν δςρχιιν αΰψδ"α εΰιψετδ εϊπΰιν ξχεαμιν ΰηψιν. γ"ψ Phillip Frost εηαψι δπδμδ περτιν ωμ IVAX, δξηζιχιν αωιςεψ λεμμ ωμ λ- 19% ξδεο ξπιεϊδ δξεπτχ ωμ IVAX, δϊηιιαε μδφαις αςγ δςιρχδ δξεφςϊ. δςιρχδ δεϊεεϊδ λςιρχδ τθεψδ ξξρ ϊηϊ ηεχι δξρ αΰψδ"α. ρβιψϊ δςιρχδ φτειδ μχψΰϊ ρεσ ωπϊ 2005 ΰε αϊηιμϊ 2006.
Lehman Brothers ε- Credit Suisse First Boston ωιξωε λιεςφιδ δτιππριν ωμ θας αςιρχδ ζε ε- UBS Investment Bankωιξω λιεςυ δτιππρι δαμςγι ωμ IVAX. διεςφιν δξωτθιιν δηιφεπιιν ωμ θας δν Willkie Farr & Gallagher LLP εθεμφ'ιπρχι ωθψο εωεϊ', ξωψγ ςεψλι γιο , εωμ IVAX ,Greenberg Traurig, LLP .
τψθι ωιηϊ εεςιγδ
θας ε- IVAX ιχιιξε ωιηϊ εεςιγδ αιεν ωπι, 25 αιεμι, 2005 αωςδ 15:30 ζξο ιωψΰμ (08:30 ζξο πιε-ιεψχ) λγι μγεο αψλιωδ. πιϊο μδΰζιο μωιηδ γψκ ΰϊψ δΰιπθψπθ ωμ θας, αλϊεαϊ: www.tevapharm.com. μΰηψ ριεν δωιηδ, πιϊο ιδιδ μδΰζιο μωιγεψ ηεζψ ςγ μιεν 1 αΰεβερθ, 2005, αηφεϊ (ωςεο πιε-ιεψχ) αΰϊψ δηαψδ, ΰε ςμ-ιγι αθμτεο αξρτψιν: 1-201-612-7415 μξηιιβιν ξηευ μΰψδ"α ε-1-877-660-6853 μξηιιβιν αϊεκ ΰψδ"α. χεγ δλπιρδ μωιγεψ δηεζψ διπε ηωαεο ξρτψ (Account #) 3055 ε- ϊε δζιδει (ID#) διπε: 162720.
ΰεγεϊ θας
θας ϊςωιεϊ τψξφαθιεϊ ας"ξ διπδ ηαψδ βμεαμιϊ ωαριρδ αιωψΰμ εΰηϊ ξ- 20 δηαψεϊ δτψξφαθιεϊ δξεαιμεϊ αςεμν. θας, δξϊξηδ αιιφεψ ϊψετεϊ βπψιεϊ ειιηεγιεϊ εαιιφεψ ηεξψιν τςιμιν μϊςωιδ δτψξφαθιϊ, διπδ ΰηϊ ξδξεαιμεϊ αςεμν αϊηεν δβπψιχδ. μθας ΰϊψι ιιφεψ, ξηχψ, ωιεεχ εδτφδ αιωψΰμ, αφτεο ΰξψιχδ εαΰιψετδ. χψεα μ- 90% ξξλιψεϊιδ ωμ δχαεφδ δο μφτεο ΰξψιχδ εΰιψετδ. δξε"τ διιηεγι ωμ θας ξϊξχγ ατιϊεη ϊψετεϊ ηγωπιεϊ μξημεϊ δτεβςεϊ αξςψλϊ δςφαιν δξψλζιϊ εμξημεϊ ΰεθε-ΰιξεπιεϊ.
ΰεγεϊ IVAX
IVAX Corporation, ωαριρδ αξιΰξι, τμεψιγδ, ξτϊηϊ ξιιφψϊ εξωεεχϊ ξεφψιν τψξφαθιιν ιιηεγιιν εβπψιιν ελο ξεφψιν εθψιπψιιν ετεςμϊ αΰψδ"α εεαωΰψ δςεμν. ΰϊψ δηαψδ: www.ivax.com.
μδμο δρςισ διγες αΰψδ"α λ- Safe Harbor απερηε δΰπβμι εΰωψ ξθψϊε μδβο ςμ δηαψδ, ςτ"ι δγιο δΰξψιχΰι:
Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on managements current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva`s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to Teva's ability to rapidly integrate Ivax Corporation's operations and achieve expected synergies, Teva`s ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell or license their own generic products under generic trade dress and at generic prices (so called "authorized generics") or seek to delay the introduction of generic products ,the impact of consolidation of our distributors and customers, regulatory changes that may prevent Teva from exploiting exclusivity periods, potential liability for sales of generic products prior to a resolution of outstanding litigation, including that relating to the generic versions of Allegra®, Neurontin®, Oxycontin® and Zithromax®, the effects of competition on Copaxone® sales, including as a result of the expected reintroduction of Tysabri® into the market, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Association and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, Teva`s ability to successfully identify, consummate and integrate acquisitions, exposure to product liability claims, dependence on patent and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism or major hostilities ,environmental risks, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on managements current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva`s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to Teva's ability to rapidly integrate Ivax Corporation's operations and achieve expected synergies, Teva`s ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell or license their own generic products under generic trade dress and at generic prices (so called "authorized generics") or seek to delay the introduction of generic products ,the impact of consolidation of our distributors and customers, regulatory changes that may prevent Teva from exploiting exclusivity periods, potential liability for sales of generic products prior to a resolution of outstanding litigation, including that relating to the generic versions of Allegra®, Neurontin®, Oxycontin® and Zithromax®, the effects of competition on Copaxone® sales, including as a result of the expected reintroduction of Tysabri® into the market, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Association and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, Teva`s ability to successfully identify, consummate and integrate acquisitions, exposure to product liability claims, dependence on patent and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism or major hostilities ,environmental risks, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
| © 1999 - 2008 λμ δζλειεϊ ωξεψεϊ μθας | ϊπΰι ωιξεω αΰϊψ | ξτϊ δΰϊψ |